(Date:7/2/2009)...SNewswire/ -- Recent news reports have highlighted...ing that physicians meet high standards in their c...Board of Medical Specialties (ABMS), which coordin...orts to develop and implement educational and prof...ation of physician specialists. Certification by ...
(Date:7/2/2009)...ire-USNewswire/ -- A new analysis of the incidence...en the ages of 0 to 84 from 2000 to 2005 shows a 7... the Ministry of Health, with the sharpest uptick ...ed (ages 25 to 44). , , The new results, which ... breast surgeries rather than official estimations...
(Date:7/2/2009)...cal issues need to be addressed in order to improv...cancer, according to a commentary published online...titute . , The biomarker pipeline to develop and...tification of promising biomarkers to detect cance... of biomarkers for cancer screening. , In the c...
(Date:7/2/2009)...USNewswire/ -- "If recent reports of DEA intervent...ace intense scrutiny from the DEA,s Diversion unit...ed Mr. Jackson,s prescriptions will also be under ...ciated with any of Jackson,s prescriptions," said ...n full federal jury acquittal at trial on a 10 cou...
Breaking Medicine News(10 mins):Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 3Health News:DEA Will Play Hardball in Investigating Michael Jackson's Doctors 2(Date:6/28/2009)...ne 29 Data presented,today, in Bu...e novel,once-daily anti-epileptic Zebinix(R)* (e... and sustained decrease in seizure frequency over ...ar extension of a pivotal Eslicarbazepine Acetate,...al Congress for Epilepsy in,Budapest, Hungary. Pa...
(Date:6/26/2009)...pan, June 27, 2009 Takeda Pharmace...that Takeda Global Research & Development Cent...idiary received on June 26 (U.S. time) a complete ...stration (FDA) regarding the Company,s New Drug Ap...idyl peptidase IV (DPP-4) inhibitor under investig...
(Date:6/26/2009)...ast Cancer Recurrence Test MammaPrint,Included in...ndations" issued,on 23 Jun 2009 12:00 GMT, by Age...t the subheadline was missing from the release as ... corrected release follows: , , /PRNewsw...e Test MammaPrint Included in,International St. G...
(Date:6/26/2009)... New Anti-TNF Therapy in Three Rheumatic Diseases ...AM, Pa. and KENILWORTH, N.J., June 26 /PRNewswire-...ring-Plough Corporation (NYSE: SGP ) announced t... Human Use (CHMP) of the European Medicines Agency...e approval of SIMPONI(TM) (golimumab) as a once-mo...
Breaking Medicine Technology:Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10European Neuroscience and Society Network tackles neurosocieties head on 12034 1European Neuroscience and Society Network tackles neurosocieties head on 12034 2Lieff Cabraser Heimann 26 Bernstein LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners Inc 12031 1Lieff Cabraser Heimann 26 Bernstein LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners Inc 12031 2Lieff Cabraser Heimann 26 Bernstein LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners Inc 12031 3Global Med Technologies 28R 29 Inc Recieves FDA 510 28K 29 Clearance for ElDorado Donor 28TM 29 12027 1Global Med Technologies 28R 29 Inc Recieves FDA 510 28K 29 Clearance for ElDorado Donor 28TM 29 12027 2Global Med Technologies 28R 29 Inc Recieves FDA 510 28K 29 Clearance for ElDorado Donor 28TM 29 12027 3Viral Therapy Slows Pediatric Tumors in Mice 12024 1Viral Therapy Slows Pediatric Tumors in Mice 12024 2...bcast to Follow,Presentation, DANBURY, Conn., June...day announced plans to present clinical results of...e 67th Annual American,Diabetes Association (ADA) ...2 through June 26. , Biodel,s oral presentation at...15pm CST, a summary of which will be available on,...
...all/ -- Advanced Life,Sciences Holdings, Inc. , to...he first of two pivotal Phase 3 clinical trials,de...ethromycin, a,novel once-a-day antibiotic, for the...In the study, cethromycin achieved,non-inferiority...cure rate compared to Biaxin(R) (clarithromycin) i...
Other Medicine Technology:Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 2Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 3Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 2Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 3Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 4Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 515mm Open Blades, Thumb Screw Control; in Titanium.
10mm from mid screw to tips; curved tips, in Titanium.
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel.
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle
Medicine Products: